EZH2 and essential thrombocythemia: In NGS studies of patients with ET or PV, inferior OS or higher risk of leukemic transformation have been associated with mutations in ASXL1 [63,146,164], SRSF2 [146,164], IDH1/2 [164], or EZH2 (only ET) [186].